ログイン
ランキング
お知らせ
ログイン
文献詳細
増大特集 アミロイド関連神経疾患のすべて―封入体筋炎からアルツハイマー病まで
文献概要
ALアミロイドーシスは，異常形質細胞が単クローン性に増殖し，その産物である免疫グログリン（M蛋白）の軽鎖に由来するアミロイド蛋白（free light chain：FLC）が，全身の諸臓器（心臓，腎臓，消化器，末梢神経など）に沈着して臓器障害をきたす疾患である。FLC，BNP，そして尿中アルブミンなどの新しいマーカーを用いた的確な早期診断と，メルファラン／デキサメタゾン併用療法，新規薬剤の併用や自家末梢血幹細胞移植などの治療で予後は著しく改善されてきている。
参考文献
1) Dispenzieri A, Gertz MA, Buadi F: What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 26: 137-154, 2012
2) Suzuki K: Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clin Exp Nephrol 16: 659-671, 2012
3) Palladini G, Merlini G: Systemic amyloidoses: what an internist should know. Eur J Intern Med 24: 729-739, 2013
4) アミロイドーシス. 公益財団法人難病医学研究財団難病情報センターホームページ: http://www.nanbyou.or.jp/sikkan/004_i.htm
5) Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, et al: Definition of organ involvement and treatment response in International Sympodium on Amyloid and Amyloidosis (AL): A Consensus Opinion From the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004．Am J Hematol 79: 319-328, 2005
6) Gertz M, Merlini G: Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion ［abstract］. Amyloid 17(Suppl 1): 48-49, 2010
7) Palladini G, Foli A, Milani P, Russo P, Albertini R, et al: Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 87: 465-471, 2012
8) Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30: 989-995, 2012
9) Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pannell DJ: Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10: 54, 2008
10) Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, et al: Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103: 544-549, 2009
11) Merlini G, Wechalekar AD, Palladini G: Systemic light chain amyloidosis: an update for treating physicians. Blood 121: 5124-5130, 2013
12) Gertz MA: Immunoglobulin light chain amyloidosis: update on diagnosis, prognosis, and treatment. Am J Hematol 88: 416-425, 2013
13) Palladini G, Russo P, Bosoni T, Verga L, Sarais G, et al: Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55: 499-504, 2009
14) Kyle RA, Gertz MA: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32: 45-59, 1995
15) Swan N, Skinner M, O'Hara CJ: Bone marrow core biopsy specimens in AL (primary) amyloidosis: a morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol 120: 610-616, 2013
16) Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, et al: Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma 51: 2181-2187, 2010
17) Moumas E, Desport E, Lacombe C, Gombert JM, Bridoux F, et al: Systemic AL amyloidosis with renal involvement in a region of western France. Amyloid 17(suppl): 151, 2010
18) Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, et al: Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119: 488-493, 2012
19) Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, et al: Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114: 4957-4959, 2009
20) Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, et al: Reliable typing of systemic amyloidosis through proteomic analysis of subcutaneous adipose tissue. Blood 119: 1844-1847, 2011
21) Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, et al: Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 19: 167-170, 2012
22) Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT: Serum test for assessment of patients with Bence Jones myeloma. Lancet 361: 489-491, 2003
23) Gay-Bellile C, Bengoufa D, Houze P, Le Carrer D, Benlakehal M, et al: Automated multicapillery electrophoresis for analysis of human serum proteins. Clin Chem 49: 1909-1915, 2003
24) Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, et al: Screening panels for detection of monoclonal gammopathies. Clin Chem 55: 1517-1522, 2009
25) Merilini G: Management of AL amyloidosis in 2013．14th International Myeloma Workshop, 2013, Kyoto
26) Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, et al: High-dose melphalan versus melphalan plus dexamethesone for AL amyloidosis. N Engl J Med 357: 1083-1093, 2007
27) 小倉美津妃, 関根理恵子, 西山小百合, 阿部 有, 飯塚浩光, 他: 大量メルファラン併用自家末梢血幹細胞移植を施行した心アミロイドーシス9例の臨床的検討. 臨床血液53: 710-715, 2012
28) Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, et al: Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118: 4346-4352, 2011
29) Schönland SO, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, et al: Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 107: 2578-2584, 2006
30) Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, et al: Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 10: 257-261, 2003
31) Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, et al: Tolerability and efficacy of thalidomide for the treatment of patients with light-chain-associated (AL) amyloidosis. Clin Lymphoma 3: 241-246, 2003
32) Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, et al: The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105: 2949-2951, 2005
33) Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, et al: Safety and efficacy of risk-adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis. Blood 109: 457-464, 2007
34) Wechalekar AD, Hawkins PN, Gillmore JD: Perspectives in treatment of AL amyloidosis. Br J Haematol 140: 365-377, 2008
35) National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Systemic Light Chain Amyloidosis, Version 1．2013
36) Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, et al: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109: 465-470, 2007
37) Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, et al: Lenalidomide combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 116: 4777-4782, 2010
38) Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, et al: Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed treatment of AL amyloidosis: results of a phase 2 trial. Blood 109: 492-496, 2007
39) Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, et al: Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalating study. Blood 114: 1489-1497, 2009
40) Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, et al: Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 92: 1351-1358, 2007
41) Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD: Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 93: 295-298, 2008
42) Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, et al: Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of phase 1/2 study. Blood 118: 865-873, 2011
43) Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, et al: Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 27: 823-828, 2013
44) Sattianayagam PT, Gibbs SD, Pinney JH, Wechalekar AD, Lachmann HJ, et al: Solid organ transplantation in AL amyloidosis. Am J Trans 10: 2124-2131, 2010
掲載誌情報
